Funding for this research was provided by:
National Institute on Drug Abuse (K12 DA043490)
Received: 19 October 2022
Accepted: 29 March 2023
First Online: 30 April 2023
: This study received MassGeneral Brigham IRB approval and all participants provided verbal informed consent to participate.
: All authors consented to manuscript submission and publication.
: Dr. Rigotti receives royalties from UpToDate, has consulted for and received research funding from Achieve Life Sciences. Dr. Wakeman receives royalties from UpToDate and has received salary support from OptumLabs, Celero Systems, and Alosa Health. Dr. Park receives royalties from UpToDate. Dr. Evins has served as a consultant to Charles River Analytics (NIDA SBIR grant) and Karuna Pharmaceuticals (Chair Data Monitoring Board) and is a founder of NirVue Technologies. No other authors have conflicts of interest to disclose.